高敏肌钙蛋白与心肌梗死通用定义的实施效果
BACKGROUND: The introduction of more sensitive cardiac troponin assays has led to increased recognition of myocardial injury in acute illnesses other than acute coronary syndrome.…
要点
- 实施高敏肌钙蛋白和通用定义后,1型心梗诊断增加11%,2型增加22%。
- 急性与慢性心肌损伤诊断分别增加36%和43%,但未带来治疗或结局改善。
- 1型心梗患者主要结局风险最高(HR 5.64),急性心肌损伤患者非心血管死亡风险最高(HR 2.65)。
核心结论
- 实施高敏肌钙蛋白检测和通用定义可识别心血管及非心血管事件高风险患者,但未伴随治疗的一致增加或结局改善。
主要发现
- 实施后1型心肌梗死诊断增加11%(510/4471),2型增加22%(205/916),急性心肌损伤增加36%(443/1233),慢性心肌损伤增加43%(389/898)。
- 与无心肌损伤者相比,1型心肌梗死主要结局风险最高(病因特异性HR 5.64,95%CI 5.12-6.22),各诊断类别间主要结局相似。
- 非心血管死亡在急性心肌损伤患者中最高(病因特异性HR 2.65,95%CI 2.33-3.01)。
- 实施后1型心肌梗死患者抗血小板治疗和血运重建略有增加,但主要结局未变(病因特异性HR 1.00,95%CI 0.82-1.21)。
- 2型心肌梗死和心肌损伤的更多识别未导致检查、治疗或结局改变。
临床怎么用
- 临床采用高敏肌钙蛋白和通用定义时,应认识到其可识别高风险患者,但需针对非1型心肌梗死患者探索二级预防策略以改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of more sensitive cardiac troponin assays has led to increased recognition of myocardial injury in acute illnesses other than acute coronary syndrome. The Universal Definition of Myocardial Infarction recommends high-sensitivity cardiac troponin testing and classification of patients with myocardial injury based on pathogenesis, but the clinical implications of implementing this guideline are not well understood. METHODS: In a stepped-wedge cluster randomized, controlled trial, we implemented a high-sensitivity cardiac troponin assay and the recommendations of the Universal Definition in 48 282 consecutive patients with suspected acute coronary syndrome. In a prespecified secondary analysis, we compared the primary outcome of myocardial infarction or cardiovascular death and secondary outcome of noncardiovascular death at 1 year across diagnostic categories. RESULTS: Implementation increased the diagnosis of type 1 myocardial infarction by 11% (510/4471), type 2 myocardial infarction by 22% (205/916), and acute and chronic myocardial injury by 36% (443/1233) and 43% (389/898), respectively. Compared with those without myocardial injury, the rate of the primary outcome was highest in those with type 1 myocardial infarction (cause-specific hazard ratio [HR] 5.64 [95% CI, 5.12-6.22]), but was similar across diagnostic categories, whereas noncardiovascular deaths were highest in those with acute myocardial injury (cause specific HR 2.65 [95% CI, 2.33-3.01]). Despite modest increases in antiplatelet therapy and coronary revascularization after implementation in patients with type 1 myocardial infarction, the primary outcome was unchanged (cause specific HR 1.00 [95% CI, 0.82-1.21]). Increased recognition of type 2 myocardial infarction and myocardial injury did not lead to changes in investigation, treatment or outcomes. CONCLUSIONS: Implementation of high-sensitivity cardiac troponin assays and the recommendations of the Universal Definition of Myocardial Infarction identified patients at high-risk of cardiovascular and noncardiovascular events but was not associated with consistent increases in treatment or improved outcomes. Trials of secondary prevention are urgently required to determine whether this risk is modifiable in patients without type 1 myocardial infarction. CLINICAL TRIAL REGISTRATION: https://www.clinicaltrials.gov. Unique identifier: NCT01852123.
引用
- Chapman AR, Adamson PD, Shah ASV, et al. High-Sensitivity Cardiac Troponin and the Universal Definition of Myocardial Infarction. Circulation. 2019. PMID: 31587565. doi:10.1161/CIRCULATIONAHA.119.042960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。